Syros Pharmaceuticals reports Q3 EPS ($1.43), consensus ($1.14)

Reports Q3 revenue $3.76M, consensus $3.94M. “Syros is entering the fourth quarter well-positioned for its next phase of growth. We are laser-focused on advancing tamibarotene for the frontline treatment of hematologic malignancies and look forward to reporting initial data from the randomized portion of SELECT-AML-1 in early December, as well as pivotal data from SELECT-MDS-1 next year,” said Nancy Simonian, M.D., Chief Executive Officer of Syros. “This is precisely the moment we hoped for when we started Syros over a decade ago: our aim has always been to deliver profound benefit to people living with serious diseases. In transitioning leadership to Conley, Syros is taking a meaningful step toward achieving this vision, installing a CEO with extensive commercial expertise and the skill set necessary to effectively build and implement a successful pre-launch and launch strategy. I look forward to continuing to support Syros as a member of the Board of Directors, and to partnering with Conley and our dedicated team as we progress our clinical trials and, ultimately, work to establish tamibarotene as the standard of care for HR-MDS and AML patients with RARA overexpression.”